Compare · ESTA vs EW
ESTA vs EW
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESTA and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $48.52B, about 24.9x ESTA ($1.95B).
- ESTA has been more active in the news (7 items in the past 4 weeks vs 5 for EW).
- EW has more recent analyst coverage (25 ratings vs 13 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- Edwards Lifesciences Corporation
- Price
- $66.24+1.69%
- $84.16+5.54%
- Market cap
- $1.95B
- $48.52B
- 1M return
- -
- +1.83%
- 1Y return
- -
- +11.37%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 7
- 5
- Recent ratings
- 13
- 25
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ESTA
- SEC Form DEFA14A filed by Establishment Labs Holdings Inc.
- Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6
- SEC Form 4 filed by Chacon Quiros Juan Jose
- SEC Form DEFA14A filed by Establishment Labs Holdings Inc.
- SEC Form DEF 14A filed by Establishment Labs Holdings Inc.
- Amendment: SEC Form 4 filed by Caldini Filippo
- Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market
- SEC Form 4 filed by Schutter Edward J
- SEC Form 4 filed by Gillin Leslie
- SEC Form 4 filed by Slotkin Bryan
Latest EW
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation
- SEC Form DEFA14A filed by Edwards Lifesciences Corporation